Search

Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Black innovators contribution to health & wellness throughout the years

Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

Business Resource Groups at Boehringer Ingelheim

Business Resource Groups at Boehringer Ingelheim contribute to and help shape our company culture.

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

Generalized Pustular Psoriasis: Impact Beyond the Skin

Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

First half 2019: High levels of investment in R&D and robust organic growth

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

AI-Driven Model Validated to Predict Risk of CKD Progression

Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Jardiance® (empagliflozin) analysis reinforces established safety profile

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.

Leticia develops product medical strategies

Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

Our goal of transforming DLL3-positive carcinomas

Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers